<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240926041414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240926041414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 26 Sep 2024 08:14:15 +0000</lastbuilddate>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322939/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 25:ehae622. doi: 10.1093/eurheartj/ehae622. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322939/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322939</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae622>10.1093/eurheartj/ehae622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322939</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection</dc:title>
<dc:identifier>pmid:39322939</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae622</dc:identifier>
</item>
<item>
<title>The burden of atrial fibrillation in the Asia-Pacific region</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 25. doi: 10.1038/s41569-024-01091-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322762</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01091-1>10.1038/s41569-024-01091-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322762</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher X Wong</dc:creator>
<dc:creator>Hung Fat Tse</dc:creator>
<dc:creator>Eue-Kuen Choi</dc:creator>
<dc:creator>Tze-Fan Chao</dc:creator>
<dc:creator>Koichi Inoue</dc:creator>
<dc:creator>Katrina Poppe</dc:creator>
<dc:creator>Eugene Tan</dc:creator>
<dc:creator>Yoga Yuniadi</dc:creator>
<dc:creator>Erdie Fadreguilan</dc:creator>
<dc:creator>Sofian Johar</dc:creator>
<dc:creator>Ngai Yin Chan</dc:creator>
<dc:creator>Narayan Namboodiri</dc:creator>
<dc:creator>S Mokaddas Hossain</dc:creator>
<dc:creator>Huang He</dc:creator>
<dc:creator>Thoranis Chantrarat</dc:creator>
<dc:creator>Abdul Raqib Bin Abd Ghani</dc:creator>
<dc:creator>Narantuya Davaakhuu</dc:creator>
<dc:creator>Nwe Nwe</dc:creator>
<dc:creator>Ghazala Irfan</dc:creator>
<dc:creator>Minh That Ton</dc:creator>
<dc:creator>Rohan Gunawardena</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The burden of atrial fibrillation in the Asia-Pacific region</dc:title>
<dc:identifier>pmid:39322762</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01091-1</dc:identifier>
</item>
<item>
<title>Cardiovascular care with digital twin technology in the era of generative artificial intelligence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322420/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>Digital twins, which are in silico replications of an individual and its environment, have advanced clinical decision-making and prognostication in cardiovascular medicine. The technology enables personalized simulations of clinical scenarios, prediction of disease risk, and strategies for clinical trial augmentation. Current applications of cardiovascular digital twins have integrated multi-modal data into mechanistic and statistical models to build physiologically accurate cardiac replicas to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae619. doi: 10.1093/eurheartj/ehae619. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Digital twins, which are in silico replications of an individual and its environment, have advanced clinical decision-making and prognostication in cardiovascular medicine. The technology enables personalized simulations of clinical scenarios, prediction of disease risk, and strategies for clinical trial augmentation. Current applications of cardiovascular digital twins have integrated multi-modal data into mechanistic and statistical models to build physiologically accurate cardiac replicas to enhance disease phenotyping, enrich diagnostic workflows, and optimize procedural planning. Digital twin technology is rapidly evolving in the setting of newly available data modalities and advances in generative artificial intelligence, enabling dynamic and comprehensive simulations unique to an individual. These twins fuse physiologic, environmental, and healthcare data into machine learning and generative models to build real-time patient predictions that can model interactions with the clinical environment to accelerate personalized patient care. This review summarizes digital twins in cardiovascular medicine and their potential future applications by incorporating new personalized data modalities. It examines the technical advances in deep learning and generative artificial intelligence that broaden the scope and predictive power of digital twins. Finally, it highlights the individual and societal challenges as well as ethical considerations that are essential to realizing the future vision of incorporating cardiology digital twins into personalized cardiovascular care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322420/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322420</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae619>10.1093/eurheartj/ehae619</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322420</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Phyllis M Thangaraj</dc:creator>
<dc:creator>Sean H Benson</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Folkert W Asselbergs</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular care with digital twin technology in the era of generative artificial intelligence</dc:title>
<dc:identifier>pmid:39322420</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae619</dc:identifier>
</item>
<item>
<title>Catheter ablation for atrial fibrillation: indications and future perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>Recent advances in techniques, technologies and proven superiority over anti-arrhythmic drugs have made catheter ablation the cornerstone of management for atrial fibrillation (AF), which has shown a steady increase in prevalence in the ageing population worldwide. The aim of therapeutic interventions is to achieve stable sinus rhythm that would improve the quality of life and reduce the risk of AF-associated complications. Pulmonary veins (PVs) were first described as the source of initiation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae618. doi: 10.1093/eurheartj/ehae618. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advances in techniques, technologies and proven superiority over anti-arrhythmic drugs have made catheter ablation the cornerstone of management for atrial fibrillation (AF), which has shown a steady increase in prevalence in the ageing population worldwide. The aim of therapeutic interventions is to achieve stable sinus rhythm that would improve the quality of life and reduce the risk of AF-associated complications. Pulmonary veins (PVs) were first described as the source of initiation of ectopic triggers driving AF, which led to the establishment of PV isolation (PVI) as the most widely practiced procedure to treat AF. Antral PVI is still recognized as the stand-alone ablation strategy for newly diagnosed paroxysmal AF (PAF). However, in non-PAF patients, PVI seems to be inadequate and several adjunctive strategies, including ablation of left atrial posterior wall and non-PV triggers, AF mapping and ablation of rotors and drivers, ethanol infusion of vein of Marshall and renal denervation, etc. have been reported with mixed results. Recent trials have also documented the benefits of early rhythm control in preventing cardiovascular events in addition to slowing the progression of PAF to more persistent forms. Similarly, very late relapse of the arrhythmia after successful PVI has drawn attention to the critical role of non-PV triggers and highlighted their relevance as potential ablation targets during repeat procedures. Ablation technology is also under constant evolution with the introduction of non-thermal energy sources and new tools to create durable lesions. This review summarizes the indications, advancements, and future perspective of AF ablation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae618>10.1093/eurheartj/ehae618</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322413</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Natale</dc:creator>
<dc:creator>Sanghamitra Mohanty</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Elad Anter</dc:creator>
<dc:creator>Ashok Shah</dc:creator>
<dc:creator>Ghaliah Al Mohani</dc:creator>
<dc:creator>Michael Haissaguerre</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Catheter ablation for atrial fibrillation: indications and future perspective</dc:title>
<dc:identifier>pmid:39322413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae618</dc:identifier>
</item>
<item>
<title>RESPONSE: DEI in the CV Workforce: Foundational for Cardiovascular Care and Critical for Improving Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1370-1371. doi: 10.1016/j.jacc.2024.07.046.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322331</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.046>10.1016/j.jacc.2024.07.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322331</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer H Mieres</dc:creator>
<dc:creator>Paul L Douglass</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RESPONSE: DEI in the CV Workforce: Foundational for Cardiovascular Care and Critical for Improving Outcomes</dc:title>
<dc:identifier>pmid:39322331</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.046</dc:identifier>
</item>
<item>
<title>DEI Is Not Dead: A Framework for Cardiology Fellowship Programs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322330/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1367-1371. doi: 10.1016/j.jacc.2024.07.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322330</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.042>10.1016/j.jacc.2024.07.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322330</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Amponsah</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>DEI Is Not Dead: A Framework for Cardiology Fellowship Programs</dc:title>
<dc:identifier>pmid:39322330</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.042</dc:identifier>
</item>
<item>
<title>Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322329/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1342-1362. doi: 10.1016/j.jacc.2024.05.081.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322329/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322329</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.081>10.1016/j.jacc.2024.05.081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322329</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Cecilia R Varga</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Francisco Leyva</dc:creator>
<dc:creator>Parta Hatamizadeh</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39322329</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.081</dc:identifier>
</item>
<item>
<title>Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1339-1341. doi: 10.1016/j.jacc.2024.07.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322328</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.033>10.1016/j.jacc.2024.07.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322328</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Allan D Sniderman</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?</dc:title>
<dc:identifier>pmid:39322328</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.033</dc:identifier>
</item>
<item>
<title>Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TRL/remnants are about 4 times more atherogenic than LDL. Variation in the causal association of non-HDL-C with CHD indicates that adjustment for percentage TRL/remnant-C may be needed for accurate risk prediction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1328-1338. doi: 10.1016/j.jacc.2024.07.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Triglyceride-rich lipoproteins and remnants (TRL/remnants) have a causal, but not yet quantified, relationship with coronary heart disease (CHD): myocardial infarction plus revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to estimate TRL/remnant per-particle atherogenicity, investigate causal relationships with inflammation, and determine whether differences in the atherogenicity of TRL/remnants and low-density lipoprotein (LDL) impact the causal association of non-high-density lipoprotein cholesterol (non-HDL-C) with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Single nucleotide polymorphisms (SNPs) (N = 1,357) identified by genome-wide association in the UK Biobank were ranked into 10 clusters according to the effect on TRL/remnant-C vs LDL-C. Mendelian randomization analysis was used to estimate for each SNP cluster CHD ORs per 10 mg/dL apolipoprotein B (apoB) and per 0.33 mmol/L non-HDL-cholesterol, and to evaluate association of TRL/remnants with biomarkers of systemic inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SNPs in cluster 1 predominantly affected LDL-C, whereas SNPs in cluster 10 predominantly affected TRL/remnant-C. CHD risk per genetically predicted increase in apoB and in non-HDL-C rose across clusters. ORs per 10 mg/dL higher apoB was 1.15 (95% CI: 1.11-1.19) in cluster 1 vs 1.70 (95% CI: 1.52-1.90) in cluster 10. Comparing ORs between these TRL/remnant-predominant and LDL-predominant clusters, we estimated that TRL/remnants were at least 3.9 (95% CI: 2.8-5.4) times more atherogenic than LDL on a per-particle basis. For non-HDL-C, CHD ORs per 0.33 mmol/L rose from 1.15 (95% CI: 1.11-1.19) for cluster 1 to 1.40 (95% CI: 1.30-1.50) for cluster 10. TRL/remnants exhibited causal relationships with inflammation, but this did not explain their greater atherogenicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TRL/remnants are about 4 times more atherogenic than LDL. Variation in the causal association of non-HDL-C with CHD indicates that adjustment for percentage TRL/remnant-C may be needed for accurate risk prediction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322327</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.034>10.1016/j.jacc.2024.07.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322327</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elias Björnson</dc:creator>
<dc:creator>Martin Adiels</dc:creator>
<dc:creator>Anders Gummesson</dc:creator>
<dc:creator>Marja-Riitta Taskinen</dc:creator>
<dc:creator>Stephen Burgess</dc:creator>
<dc:creator>Chris J Packard</dc:creator>
<dc:creator>Jan Borén</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol</dc:title>
<dc:identifier>pmid:39322327</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.034</dc:identifier>
</item>
<item>
<title>Can the Excess Cardiovascular Risk Caused by Chronic Kidney Disease Be Canceled Out?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1325-1327. doi: 10.1016/j.jacc.2024.06.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322326</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.044>10.1016/j.jacc.2024.06.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322326</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carmine Zoccali</dc:creator>
<dc:creator>Francesca Mallamaci</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can the Excess Cardiovascular Risk Caused by Chronic Kidney Disease Be Canceled Out?</dc:title>
<dc:identifier>pmid:39322326</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.044</dc:identifier>
</item>
<item>
<title>Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322325/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with CKD who had controlled blood pressure, lipids, and glucose showed no excess risk of death, myocardial infarction, or stroke compared to the general population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1313-1324. doi: 10.1016/j.jacc.2024.06.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with chronic kidney disease (CKD) are at an elevated risk of cardiovascular disease (CVD) and premature mortality compared to the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate whether the excess risk of CVD events and death among patients with CKD could be reduced or eliminated through strict control of blood pressure (systolic blood pressure: &lt;130 mm Hg), lipids (low-density lipoprotein cholesterol: &lt;2.6 mmol/L), and glucose (fasting blood glucose: &lt;6.1 mmol/L).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors included 20,254 patients with CKD who were free of CVD or end-stage renal disease and matched them with 35,236 control individuals based on age (±2 years) and sex from the Kailuan study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During a median follow-up period of 12.2 to 12.8 years, 3,875 deaths, 1,888 cases of stroke, 513 cases of myocardial infarction, and 4,825 cases of CKD progression were documented. Among patients with CKD, risk factor controls showed an association with a reduction in myocardial infarction, stroke, CKD progression, and all-cause mortality risk in a dose-dependent manner. Moreover, compared to the non-CKD control individuals, having all 3 risk factors within the target ranges could theoretically eliminate the excess risk of CVD and mortality associated with CKD. Among patients with CKD who had all 3 risk factors controlled, the HRs were 0.80 (95% CI: 0.56-1.14) for myocardial infarction, 0.93 (95% CI: 0.78-1.12) for stroke, and 1.10 (95% CI: 0.98-1.24) for all-cause mortality compared to the non-CKD control individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with CKD who had controlled blood pressure, lipids, and glucose showed no excess risk of death, myocardial infarction, or stroke compared to the general population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322325/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322325</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.041>10.1016/j.jacc.2024.06.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322325</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tingting Geng</dc:creator>
<dc:creator>Wenqi Xu</dc:creator>
<dc:creator>Huanqing Gao</dc:creator>
<dc:creator>Jijuan Zhang</dc:creator>
<dc:creator>Jiaojiao Zou</dc:creator>
<dc:creator>Kaiyue Wang</dc:creator>
<dc:creator>Junjuan Li</dc:creator>
<dc:creator>Lu Guo</dc:creator>
<dc:creator>Guodong Wang</dc:creator>
<dc:creator>Shuohua Chen</dc:creator>
<dc:creator>Tao Huang</dc:creator>
<dc:creator>An Pan</dc:creator>
<dc:creator>Xiang Gao</dc:creator>
<dc:creator>Shouling Wu</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults</dc:title>
<dc:identifier>pmid:39322325</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.041</dc:identifier>
</item>
<item>
<title>Enabling Medical Therapy for Heart Failure: New Tools Bring a New Reality for Hyperkalemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322324/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1309-1312. doi: 10.1016/j.jacc.2024.05.080.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322324/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322324</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.080>10.1016/j.jacc.2024.05.080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322324</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Aferdita Spahillari</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Enabling Medical Therapy for Heart Failure: New Tools Bring a New Reality for Hyperkalemia</dc:title>
<dc:identifier>pmid:39322324</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.080</dc:identifier>
</item>
<item>
<title>Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322323/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1295-1308. doi: 10.1016/j.jacc.2024.05.079.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) run-in phase.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with HFrEF and HK or past HK entered a run-in phase of ≤12 weeks with patiromer-facilitated RAS inhibitor/MRA optimization to achieve ≥50% recommended RAS inhibitor dose, 50 mg/d MRA, and normokalemia. Patients achieving these criteria (randomized group) were compared with the run-in failure group (patients not meeting the randomization criteria).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,038 patients completing the run-in, 878 (84.6%) were randomized and 160 (15.4%) were run-in failures. Overall, 422 (40.7%) had HK entering run-in with a similar frequency in the randomized and run-in failure groups (40.3% vs 42.5%; P = 0.605). From start to the end of run-in, in the randomized group, an increase was observed in target RAS inhibitor and MRA use in patients with HK (RAS inhibitor: 76.8% to 98.6%; MRA: 35.9% to 98.6%) and past HK (RAS inhibitor: 60.5% to 98.1%; MRA: 15.6% to 98.7%). Despite not meeting the randomization criteria, an increase after run-in was observed in the run-in failure group in target RAS inhibitor (52.5% to 70.6%) and MRA use (15.0% to 48.1%). This increase was observed in patients with HK (RAS inhibitor: 51.5% to 64.7%; MRA: 19.1% to 39.7%) and past HK (RAS inhibitor: 53.3% to 75.0%; MRA: 12.0% to 54.3%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322323/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322323</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.079>10.1016/j.jacc.2024.05.079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322323</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Andrew J S Coats</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Patrick Rossignol</dc:creator>
<dc:creator>Matthew R Weir</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Ileana L Piña</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Cecilia Bahit</dc:creator>
<dc:creator>Jan Belohlavek</dc:creator>
<dc:creator>Jasper J Brugts</dc:creator>
<dc:creator>Amandine Perrin</dc:creator>
<dc:creator>Sandra Waechter</dc:creator>
<dc:creator>Jeffrey Budden</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia</dc:title>
<dc:identifier>pmid:39322323</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.079</dc:identifier>
</item>
<item>
<title>Vascular Ring Surgery: Past, Present, and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1293-1294. doi: 10.1016/j.jacc.2024.06.043.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322322</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.043>10.1016/j.jacc.2024.06.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322322</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carl L Backer</dc:creator>
<dc:creator>Constantine D Mavroudis</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Vascular Ring Surgery: Past, Present, and Future</dc:title>
<dc:identifier>pmid:39322322</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.043</dc:identifier>
</item>
<item>
<title>Outcomes of Patients Undergoing Surgery for Complete Vascular Rings</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322321/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Surgery for complete vascular rings provides good symptomatic relief with low risk of complications, whereas reoperations for aerodigestive symptoms are infrequent.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1279-1292. doi: 10.1016/j.jacc.2024.05.078.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Few studies describe outcomes after complete vascular ring surgery in a comprehensive manner.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to describe the clinical presentation, diagnostic work-up, operative approach, and outcomes in children undergoing surgery for complete vascular rings.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This single-center retrospective cohort study includes consecutive patients (January 1990 through September 2023) undergoing primary surgery for complete vascular rings, or rerepair after primary surgery elsewhere. The primary outcome of interest was complete (as distinct from partial) symptom resolution at latest clinic follow-up. Our current preference is to pursue a comprehensive initial operation including adjunctive vascular and airway procedures targeting common causes of residual aerodigestive symptoms, such as Kommerell diverticulum resection and tracheobronchopexy. Preoperative work-up routinely involved computed tomographic angiography, dynamic bronchoscopy, and laryngoscopy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 515 patients (including 39 rerepairs), the most common diagnoses were right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum (n = 323, 62.7%) and double aortic arch (n = 174, 33.8%). There was no perioperative mortality. Chylothorax occurred in 28 patients (5.4%), vocal cord dysfunction in 22 patients (4.3%), and diaphragm paralysis in 2 patients (0.4%). Follow-up was available on 453 patients (88.0%) with a median duration of 3.0 years (Q1-Q3: 0.6-9.2 years). At latest clinic follow-up, 429 patients (94.7%) reported complete symptom resolution. The risk of reoperation for residual or recurrent aerodigestive symptoms was 9.6% (95% CI: 5.7%-13.5%) at 10 years and 12.4% at 20 years (95% CI: 6.9%-17.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Surgery for complete vascular rings provides good symptomatic relief with low risk of complications, whereas reoperations for aerodigestive symptoms are infrequent.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322321/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39322321</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.078>10.1016/j.jacc.2024.05.078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322321</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ajami Gikandi</dc:creator>
<dc:creator>Peter Chiu</dc:creator>
<dc:creator>Naomi Crilley</dc:creator>
<dc:creator>Jennifer Brown</dc:creator>
<dc:creator>Lianne Cole</dc:creator>
<dc:creator>Sitaram Emani</dc:creator>
<dc:creator>Francis Fynn Thompson</dc:creator>
<dc:creator>Benjamin Zendejas</dc:creator>
<dc:creator>Christopher Baird</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes of Patients Undergoing Surgery for Complete Vascular Rings</dc:title>
<dc:identifier>pmid:39322321</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.078</dc:identifier>
</item>
<item>
<title>Emergence of community behaviors in the gut microbiota upon drug treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39321801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>Pharmaceuticals can directly inhibit the growth of gut bacteria, but the degree to which such interactions manifest in complex community settings is an open question. Here, we compared the effects of 30 drugs on a 32-species synthetic community with their effects on each community member in isolation. While most individual drug-species interactions remained the same in the community context, communal behaviors emerged in 26% of all tested cases. Cross-protection during which drug-sensitive...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 19:S0092-8674(24)00966-8. doi: 10.1016/j.cell.2024.08.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pharmaceuticals can directly inhibit the growth of gut bacteria, but the degree to which such interactions manifest in complex community settings is an open question. Here, we compared the effects of 30 drugs on a 32-species synthetic community with their effects on each community member in isolation. While most individual drug-species interactions remained the same in the community context, communal behaviors emerged in 26% of all tested cases. Cross-protection during which drug-sensitive species were protected in community was 6 times more frequent than cross-sensitization, the converse phenomenon. Cross-protection decreased and cross-sensitization increased at higher drug concentrations, suggesting that the resilience of microbial communities can collapse when perturbations get stronger. By metabolically profiling drug-treated communities, we showed that both drug biotransformation and bioaccumulation contribute mechanistically to communal protection. As a proof of principle, we molecularly dissected a prominent case: species expressing specific nitroreductases degraded niclosamide, thereby protecting both themselves and sensitive community members.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39321801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39321801</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.037>10.1016/j.cell.2024.08.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39321801</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarela Garcia-Santamarina</dc:creator>
<dc:creator>Michael Kuhn</dc:creator>
<dc:creator>Saravanan Devendran</dc:creator>
<dc:creator>Lisa Maier</dc:creator>
<dc:creator>Marja Driessen</dc:creator>
<dc:creator>André Mateus</dc:creator>
<dc:creator>Eleonora Mastrorilli</dc:creator>
<dc:creator>Ana Rita Brochado</dc:creator>
<dc:creator>Mikhail M Savitski</dc:creator>
<dc:creator>Kiran R Patil</dc:creator>
<dc:creator>Michael Zimmermann</dc:creator>
<dc:creator>Peer Bork</dc:creator>
<dc:creator>Athanasios Typas</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Emergence of community behaviors in the gut microbiota upon drug treatment</dc:title>
<dc:identifier>pmid:39321801</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.037</dc:identifier>
</item>
<item>
<title>Microbial transformation of dietary xenobiotics shapes gut microbiome composition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39321800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>Diet is a major determinant of gut microbiome composition, and variation in diet-microbiome interactions may contribute to variation in their health consequences. To mechanistically understand these relationships, here we map interactions between ∼150 small-molecule dietary xenobiotics and the gut microbiome, including the impacts of these compounds on community composition, the metabolic activities of human gut microbes on dietary xenobiotics, and interindividual variation in these traits....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 19:S0092-8674(24)00967-X. doi: 10.1016/j.cell.2024.08.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Diet is a major determinant of gut microbiome composition, and variation in diet-microbiome interactions may contribute to variation in their health consequences. To mechanistically understand these relationships, here we map interactions between ∼150 small-molecule dietary xenobiotics and the gut microbiome, including the impacts of these compounds on community composition, the metabolic activities of human gut microbes on dietary xenobiotics, and interindividual variation in these traits. Microbial metabolism can toxify and detoxify these compounds, producing emergent interactions that explain community-specific remodeling by dietary xenobiotics. We identify the gene and enzyme responsible for detoxification of one such dietary xenobiotic, resveratrol, and demonstrate that this enzyme contributes to interindividual variation in community remodeling by resveratrol. Together, these results systematically map interactions between dietary xenobiotics and the gut microbiome and connect toxification and detoxification to interpersonal differences in microbiome response to diet.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39321800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39321800</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.038>10.1016/j.cell.2024.08.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39321800</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elizabeth J Culp</dc:creator>
<dc:creator>Nora T Nelson</dc:creator>
<dc:creator>Andrew A Verdegaal</dc:creator>
<dc:creator>Andrew L Goodman</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Microbial transformation of dietary xenobiotics shapes gut microbiome composition</dc:title>
<dc:identifier>pmid:39321800</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.038</dc:identifier>
</item>
<item>
<title>Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39320905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cohort study reveal that hospital variability in GDMT score, clinical outcomes, and costs was significant. Higher GDMT score at discharge was associated with lower mortality, lower mortality or hospitalization, more home time, and lower cost. Efforts to increase health care value should include GDMT optimization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 25. doi: 10.1001/jamacardio.2024.2969. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: A composite score for guideline-directed medical therapy (GDMT) for patients with heart failure (HF) is associated with increased survival. Whether hospital performance according to a GDMT score is associated with a broader array of clinical outcomes at lower costs is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To evaluate hospital variability in GDMT score at discharge, 90-day risk-standardized clinical outcomes and costs, and associations between hospital GDMT score and clinical outcomes and costs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 2015 to September 2019. Included for analysis were patients hospitalized for HF with reduced ejection fraction (HFrEF) in the Get With the Guidelines-Heart Failure Registry, a national hospital-based quality improvement registry. Study data were analyzed from July 2022 to April 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: GDMT score at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hospital variability in GDMT score, a weighted index from 0 to 1 of GDMT prescribed divided by the number of medications eligible, at discharge was evaluated using a generalized linear mixed model using the hospital as a random effect and quantified with the adjusted median odds ratio (AMOR). Parallel analyses centering on 90-day mortality, HF rehospitalization, mortality or HF rehospitalization, home time, and costs were performed. Costs were assessed from the perspective of the Centers of Medicare &amp; Medicaid Services. Associations between hospital GDMT score and clinical outcomes and costs were evaluated using Spearman coefficients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 41 161 patients (median [IQR] age, 78 [71-85] years; 25 546 male [62.1%]) across 360 hospitals, there was significant hospital variability in GDMT score at discharge (AMOR, 1.23; 95% CI, 1.21-1.26), clinical outcomes (mortality AMOR, 1.17; 95% CI, 1.14-1.24; HF rehospitalization AMOR, 1.22; 95% CI, 1.18-1.27; mortality or HF rehospitalization AMOR, 1.21; 95% CI, 1.18-1.26; home time AMOR, 1.07; 95% CI, 1.06-1.10) and costs (AMOR, 1.23; 95% CI, 1.21-1.26). Higher hospital GDMT score was associated with lower hospital mortality (Spearman ρ, -0.22; 95% CI, -0.32 to -0.12; P &lt; .001), lower mortality or HF rehospitalization (Spearman ρ, -0.17; 95% CI, -0.26 to -0.06; P = .002), more home time (Spearman ρ, 0.14; 95% CI, 0.03-0.24; P = .01), and lower cost (Spearman ρ, -0.11; 95% CI, -0.21 to 0; P = .047) but not with HF rehospitalization (Spearman ρ, -0.10; 95% CI, -0.20 to 0; P = .06).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cohort study reveal that hospital variability in GDMT score, clinical outcomes, and costs was significant. Higher GDMT score at discharge was associated with lower mortality, lower mortality or hospitalization, more home time, and lower cost. Efforts to increase health care value should include GDMT optimization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39320905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39320905</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2969>10.1001/jamacardio.2024.2969</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39320905</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Vincenzo B Polsinelli</dc:creator>
<dc:creator>Jie-Lena Sun</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Karen Chiswell</dc:creator>
<dc:creator>Gary K Grunwald</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Pamela Peterson</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:creator>P Michael Ho</dc:creator>
<dc:creator>Paul L Hess</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs</dc:title>
<dc:identifier>pmid:39320905</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2969</dc:identifier>
</item>
<item>
<title>Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic Cardiomyopathy: A Multicenter Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39320884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, quantitative LGE was a risk factor for SCD in patients younger than 21 years with HCM and improved risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 25. doi: 10.1001/jamacardio.2024.2824. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The ability to predict sudden cardiac death (SCD) in children and adolescents with hypertrophic cardiomyopathy (HCM) is currently inadequate. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) imaging is associated with SCD events in adults with HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the prognostic significance of LGE in patients with HCM who are younger than 21 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This multicenter, retrospective cohort study was conducted from April 8, 2015, to September 12, 2022, in patients with HCM who were younger than 21 years and had undergone CMR imaging across multiple sites in the US, Europe, and South America. Observers of CMR studies were masked toward outcomes and demographic characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Natural history of HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary outcome was SCD and surrogate events, including resuscitated cardiac arrest and appropriate discharges from an implantable defibrillator. Continuous and categorical data are expressed as mean (SD), median (IQR), or number (percentage), respectively. Survivor curves comparing patients with and without LGE were constructed by the Kaplan-Meier method, and likelihood of subsequent clinical events was further evaluated using univariate and multivariable Cox proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 700 patients from 37 international centers, median (IQR) age was 14.8 (11.9-17.4) years, and 518 participants (74.0%) were male. During a median (IQR) [range] follow-up period of 1.9 (0.5-4.1) [0.1-14.8] years, 35 patients (5.0%) experienced SCD or equivalent events. LGE was present in 230 patients (32.9%), which constituted an mean (SD) burden of 5.9% (7.3%) of left ventricular myocardium. The LGE amount was higher in older patients and those with greater left ventricular mass and maximal wall thickness; patients with LGE had lower left ventricular ejection fractions and larger left atrial diameters. The presence and burden of LGE was associated with SCD, even after correcting for existing risk stratification tools. Patients with 10% or more LGE, relative to total myocardium, had a higher risk of SCD (unadjusted hazard ratio [HR], 2.19; 95% CI, 1.59-3.02; P &lt; .001). Furthermore, the addition of LGE burden improved the performance of the HCM Risk-Kids score (before LGE addition: 0.66; 95% CI, 0.58-0.75; after LGE addition: 0.73; 95% CI, 0.66-0.81) and Precision Medicine in Cardiomyopathy score (before LGE addition: 0.68; 95% CI, 0.49-0.77; after LGE addition: 0.73; 95% CI, 0.64-0.82) SCD predictive models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, quantitative LGE was a risk factor for SCD in patients younger than 21 years with HCM and improved risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39320884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39320884</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2824>10.1001/jamacardio.2024.2824</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39320884</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Raymond H Chan</dc:creator>
<dc:creator>Laurine van der Wal</dc:creator>
<dc:creator>Gabriela Liberato</dc:creator>
<dc:creator>Ethan Rowin</dc:creator>
<dc:creator>Jonathan Soslow</dc:creator>
<dc:creator>Shiraz Maskatia</dc:creator>
<dc:creator>Sherwin Chan</dc:creator>
<dc:creator>Amee Shah</dc:creator>
<dc:creator>Mark Fogel</dc:creator>
<dc:creator>Lazaro Hernandez</dc:creator>
<dc:creator>Shafkat Anwar</dc:creator>
<dc:creator>Inga Voges</dc:creator>
<dc:creator>Marcus Carlsson</dc:creator>
<dc:creator>Sujatha Buddhe</dc:creator>
<dc:creator>Kai Thorsten Laser</dc:creator>
<dc:creator>Gerald Greil</dc:creator>
<dc:creator>Emanuela Valsangiacomo-Buechel</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Derek Wong</dc:creator>
<dc:creator>Cordula Wolf</dc:creator>
<dc:creator>Heynric Grotenhuis</dc:creator>
<dc:creator>Carsten Rickers</dc:creator>
<dc:creator>Kan Hor</dc:creator>
<dc:creator>Tobias Rutz</dc:creator>
<dc:creator>Shelby Kutty</dc:creator>
<dc:creator>Margaret Samyn</dc:creator>
<dc:creator>Tiffanie Johnson</dc:creator>
<dc:creator>Keren Hasbani</dc:creator>
<dc:creator>Jeremy P Moore</dc:creator>
<dc:creator>Ludger Sieverding</dc:creator>
<dc:creator>Jon Detterich</dc:creator>
<dc:creator>Rodrigo Parra</dc:creator>
<dc:creator>Paweena Chungsomprasong</dc:creator>
<dc:creator>Olga Toro-Salazar</dc:creator>
<dc:creator>Arno A W Roest</dc:creator>
<dc:creator>Sven Dittrich</dc:creator>
<dc:creator>Henrik Brun</dc:creator>
<dc:creator>Joseph Spinner</dc:creator>
<dc:creator>Wyman Lai</dc:creator>
<dc:creator>Adrian Dyer</dc:creator>
<dc:creator>Robert Jablonowsk</dc:creator>
<dc:creator>Christian Meierhofer</dc:creator>
<dc:creator>Dominik Gabbert</dc:creator>
<dc:creator>Milan Prsa</dc:creator>
<dc:creator>Jyoti Kandlikar Patel</dc:creator>
<dc:creator>Andreas Hornung</dc:creator>
<dc:creator>Simone Goa Diab</dc:creator>
<dc:creator>Aswathy Vaikom House</dc:creator>
<dc:creator>Harry Rakowski</dc:creator>
<dc:creator>Lee Benson</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Lars Grosse-Wortmann</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic Cardiomyopathy: A Multicenter Cohort Study</dc:title>
<dc:identifier>pmid:39320884</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2824</dc:identifier>
</item>
<item>
<title>Additional Lesion Sets in Ablation of Outflow Tract Premature Ventricular Contractions: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39320873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This randomized clinical trial showed a benefit of additional ablation in reducing the recurrence of OT-PVCs compared with the single-point ablation strategy, without increased complication risk. Additional ablations surrounding the index effective ablation point should be considered in OT-PVC ablation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 25. doi: 10.1001/jamacardio.2024.2975. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Recurrence remains a challenge after ablation of outflow tract premature ventricular contractions (OT-PVCs). Although adding additional lesions next to the index effective ablation site is sometimes performed to reinforce the ablation, it remains uncertain whether this approach is effective.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that additional ablation lesions would reduce the recurrence rate compared with single-point ablation at the index effective site for the ablation of OT-PVCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This study was a multicenter, prospective, randomized clinical trial. Patients receiving their first catheter ablation for OT-PVCs were enrolled from 18 hospitals in China between October 2021 and February 2023. Scheduled follow-up duration was 3 months after the procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: After identifying the target point and eliminating the PVC by a single-point ablation, patients were randomized 1:1 into an additional ablation group or a control group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point of the study was freedom from PVC recurrence (≥80% reduction of PVC burden, which is the number of PVCs in 24 hours/total heartbeats in 24 hours × 100%) from baseline to 3 months postprocedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 308 patients enrolled in the study, 286 (mean [SD] age, 49.2 [14.6] years; 173 female [60.5%]) were randomized to the additional ablation or the control group. The additional ablation group had a mean (SD) of 6.3 (1.1) radiofrequency applications, whereas the control group (single-point ablation group) had a mean (SD) of 1 (0) radiofrequency application. After a median (IQR) follow-up of 3.2 (0) months, the rate of freedom from PVCs was significantly higher in the additional ablation group (139 of 142 [97.9%]) compared with the control group (115 of 139 [82.7%]; P &lt; .001). Patients in the additional ablation group also had a more substantial reduction in PVC burden than the control group (mean [SD] reduction, 23.0% [10.5%] vs 19.0% [10.4%]; P = .002). There were no severe periprocedural complications in either group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This randomized clinical trial showed a benefit of additional ablation in reducing the recurrence of OT-PVCs compared with the single-point ablation strategy, without increased complication risk. Additional ablations surrounding the index effective ablation point should be considered in OT-PVC ablation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: Chinese Clinical Trials Registry Identifier: ChiCTR2200055340.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39320873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39320873</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2975>10.1001/jamacardio.2024.2975</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39320873</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kexin Wang</dc:creator>
<dc:creator>Fu Yi</dc:creator>
<dc:creator>Fangyi Xiao</dc:creator>
<dc:creator>Cao Zou</dc:creator>
<dc:creator>Yuzhen Zhang</dc:creator>
<dc:creator>Yuegang Wang</dc:creator>
<dc:creator>Linsheng Shi</dc:creator>
<dc:creator>Chengzong Li</dc:creator>
<dc:creator>Long Chen</dc:creator>
<dc:creator>Shuanglun Xie</dc:creator>
<dc:creator>Wenzhi Shen</dc:creator>
<dc:creator>Ning Zhang</dc:creator>
<dc:creator>Qiang Wu</dc:creator>
<dc:creator>Qiang Xu</dc:creator>
<dc:creator>Yuan Ji</dc:creator>
<dc:creator>Cheng Wang</dc:creator>
<dc:creator>Zhiyu Lin</dc:creator>
<dc:creator>Youquan Wei</dc:creator>
<dc:creator>Zhongbao Ruan</dc:creator>
<dc:creator>Yumin Sun</dc:creator>
<dc:creator>Weizhu Ju</dc:creator>
<dc:creator>Minglong Chen</dc:creator>
<dc:creator>OT-PVCs Study Investigators</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Additional Lesion Sets in Ablation of Outflow Tract Premature Ventricular Contractions: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39320873</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2975</dc:identifier>
</item>
<item>
<title>The Cotton Plant</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39320872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926041414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 25. doi: 10.1001/jamacardio.2024.2960. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39320872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926041414&v=2.18.0.post9+e462414">39320872</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2960>10.1001/jamacardio.2024.2960</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39320872</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Naila A Khan</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Cotton Plant</dc:title>
<dc:identifier>pmid:39320872</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2960</dc:identifier>
</item>





























</channel>
</rss>